75Health

Main Menu

  • Home
  • About Us
  • Services
    • Electronic Health Records
    • Electronic Medical Records
    • Personal Health Records
    • Practice Management Software
    • EHR and EMR Providers
  • Go back to 75health.com

logo

75Health

  • Home
  • About Us
  • Services
    • Electronic Health Records
    • Electronic Medical Records
    • Personal Health Records
    • Practice Management Software
    • EHR and EMR Providers
  • Go back to 75health.com
Blog
Home›Blog›‘Apollo 11 Moment’: Two Monoclonal Antibody Trials for COVID Launched.

‘Apollo 11 Moment’: Two Monoclonal Antibody Trials for COVID Launched.

By 75health
August 5, 2020
171
0

Officials from the National Institutes of Health (NIH) and Eli Lilly and Company today announced the launch of two clinical trials that will examine the investigational monoclonal antibody LY-CoV555 for the treatment of COVID-19. One trial will include outpatients, and the other will include hospitalized patients.

75health Signup

“This is a significant day, but it’s also an example of how the best clinical science can only happen with public participation,” NIH Director Francis Collins, MD, PhD, said during a press briefing. “We will be earnestly seeking individuals who’ve been found to be infected with SARS-CoV-2 virus and who are interested in taking part in seeking answers to a critical question: can monoclonal antibodies reduce severity of COVID-19? Can that approach even save lives?”

Colorized scanning electron micrograph of a cell heavily infected with SARS-COV-2 virus particles, isolated from a patient sample.

The news marks the latest development in efforts from the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, a public-private partnership that was launched in April 2020 to speed development of the most promising treatments and vaccine candidates. The effort includes seven government partners, 20 industry partners, and three nonprofit partners.

The LY-CoV555 antibody was discovered in a blood sample from a recovered COVID-19 patient in the state of Washington by Vancouver, British Columbia–based AbCellera Biologics in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID). Following this, Lilly Research Laboratories partnered with AbCellera to develop and manufacture LY-CoV555.

In ACTIV-2, a phase 2 trial, investigators plan to study the safety and efficacy of LY-CoV555 in 200 people with mild to moderate symptoms of COVID-19 who have not been hospitalized. Half will receive the monoclonal antibody, and the other half will receive placebo. To be eligible, study participants must have tested positive for COVID-19 within 7 days and have experienced symptoms within 10 days.

During the briefing, NIAID Director Anthony Fauci, MD, said that the primary objective of ACTIV-2 is “to determine whether the investigational treatment reduces the duration of symptoms through 28 days and increases the proportion of the volunteers who have undetectable virus in the nasopharynx at various periods of time ranging from 3 days to 28 days. If transitioned to phase 3, [this trial will] determine if in fact the intervention reduces the risk of hospitalization and/or death.”

The other trial being launched, ACTIV-3, is a phase 3 study that will examine the safety and efficacy of LY-CoV555 in 300 hospitalized patients. Half will receive the monoclonal antibody, and the other half will receive placebo.

75Health getstarted

If the treatment appears to be effective, “this will go on to a second phase of 700 individuals, for a total of 1000 [patients],” Fauci said. “The entry criteria for this trial are symptoms [of COVID-19] for 12 days or less, requiring hospitalization but without end-stage organ failure. The primary objective is a sustained recovery for 14 days at home after hospital discharge.”

Source : https://www.medscape.com/viewarticle/935170

 

TagsdoctorElectronic Medical Record ProvidersEMR Providershealthhealth careHospitalMedical
Previous Article

FDA Approves Cannabidiol for Tuberous Sclerosis Complex.

Next Article

How to dramatically reduce inappropriate ulcer-prevention prescriptions.

Related articles More from author

  • Blog

    Electronic Medical Records rEvolution.

    December 1, 2020
    By 75health
  • Blog

    Significant highlights of Medical Billing Software.

    January 7, 2021
    By 75health
  • Blog

    Important Features of Medical Billing Software

    January 5, 2021
    By 75health
  • Blog

    FDA Approves Cannabidiol for Tuberous Sclerosis Complex.

    August 4, 2020
    By 75health
  • Blog

    Regarding My Health Record:

    October 16, 2020
    By 75health
  • Blog

    Empowering the Health of Elderly People with E-Prescribing Software.

    January 15, 2021
    By 75health

Leave a reply Cancel reply

  • Newsroom

    Kaaspro: Bringing Doctors & Patients Together

  • Major responsibilities and interactions of professionals with the EHR system
    EHR

    Major responsibilities and interactions of professionals with the EHR system

  • Blog

    Why Medical Billing Software for Healthcare Industry?

Popular Post

  • What Components Constitute an Electronic Health Record? What Components Constitute an Electronic Health Record? 9 views
  • What is the purpose of using EHR? What is the purpose of using EHR? 7 views
  • 7 Essential Oils That Support Women’s Health 7 Essential Oils That Support Women’s Health 6 views
  • What are the Important Components of Medical Practice Management Software? What are the Important Components of Medical Practice Management Software? 5 views
  • Top 5 Ways to improve your EHR practice workflow Top 5 Ways to improve your EHR practice workflow 5 views

75Health Video

Email Subscribers

Email *

Interested?

Demo Video
Private cloud
White labeling
Partnership

Services

Electronic Health Records
Electronic Medical Records
Personal Health Records
Practice Management Software
EHR and EMR Providers

Company

About us
Contact us
Terms
Privacy Policy
Sitemap

Address

USA
77 Stonebrae Rd
Hayward CA 94542
India
147, Rajiv Ganghi Salai, OMR,
Elcot Sez, Sholinganallur,
Chennai, Tamil Nadu 600119.

   +1-415-877-3032          +91-95666-74450
© 2020 www.75Health.com. All Rights Reserved.